Drug Profile
JNJ 64400141
Alternative Names: Ad26-RSV-preF; Ad26.RSV.preF; Ad26.RSV.preF-based vaccine; Adenovirus Serotype 26 (Ad26.RSV.preF)-based vaccine; JNJ-64400141; RSV Jr prophylactic vaccine - Janssen; RSV Senior prophylactic vaccine - Janssen; VAC-18193; VAC-18194Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Janssen Vaccines and Prevention B.V
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Respiratory syncytial virus infections
Most Recent Events
- 03 Aug 2023 Janssen Vaccine and Prevention completes a phase II CYPRESS trial in Respiratory syncytial virus infections (Prevention, In the elderly) in USA (IM) (NCT03982199)
- 17 May 2023 Janssen Pharmaceutical terminates a phase III trial in Respiratory syncytial virus infections (In the elderly, Prevention, In adults) in Japan (IM) due to sponsor's decision (NCT05242432)
- 30 Mar 2023 Discontinued - Phase-III for Respiratory syncytial virus infections (In the elderly, Prevention, In adults) in Germany, USA, Poland, Estonia, Canada, Australia, Brazil, Chile, China, Finland, New Zealand, South Africa, Taiwan, Thailand (IM)